• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

FDA Warning On Safety of Diabetes Drug

Article

Onglyza (saxagliptin), developed by AstraZeneca, was found to cause an increased risk of heart failure.

AstraZeneca Plc's diabetes drug Onglyza (saxagliptin) may be associated with an increased rate of death, according to a preliminary review of data by the FDA.

The FDA's report, posted on the agency's website on Friday, comes ahead of an April 14 meeting of an FDA advisory panel to discuss the drug's safety. A company-sponsored trial of more than 16,000 patients known as SAVOR previously showed patients taking Onglyza had an increased risk of hospitalizations due to heart failure.

The agency's analysis found the heart failure risk valid. It also identified a possible increased risk of death from all causes.

Complete article on Medpage:

http://bit.ly/1FDuFKp

Related Videos
Ian Neeland, MD
Chase D. Hendrickson, MD, MPH
Steven Coca, MD, MS, Icahn School of Medicine, Mount Sinai
Javed Butler, MD, MPH, MBA
Jennifer Sturgill, DO, Central Ohio Primary Care
Zachary Cox, PharmD
Matthew Crowley, MD, MHS, associate professor of medicine, Duke University School of Medicine.
Susan Spratt, MD, senior medical director, Duke Population Health Management Office, associate professor of medicine, division of Endocrinology, Metabolism, and Nutrition,
Zachary Cox, PharmD
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.